Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
Starglo isn't applicable to a US population, an adcom rules.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
